{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:12:09Z","timestamp":1772165529051,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T00:00:00Z","timestamp":1593388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Biotest AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The effects of intravenous immunoglobulin G replacement on perceived health and infection susceptibility of patients suffering from immunoglobulin G (IgG) deficiencies should be evaluated in a prospective analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with symptomatic primary or secondary IgG deficiencies were interviewed prior to the first IgG infusion (t\n                      <jats:sub>0<\/jats:sub>\n                      ) and over the course of their treatment (t\n                      <jats:sub>1<\/jats:sub>\n                      - t\n                      <jats:sub>6<\/jats:sub>\n                      ). The respondents rated their current health using a 100 point scale (EQ-5D-5L), ranging from 0 (\u2018worst imaginable health\u2019) to 100 (\u2018best imaginable health\u2019). The patients also provided information on the frequency of infections and of infections requiring antibiotics in the past 8\u2009weeks. A healthy control group (CG) without oncologic diseases answered the questions once.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred six patients with a median age of 65\u2009years (21\u201385\u2009years) were investigated. The median serum IgG concentration changed from 500\u2009mg\/dl (t\n                      <jats:sub>0<\/jats:sub>\n                      ) to 772\u2009mg\/dl (t\n                      <jats:sub>6<\/jats:sub>\n                      ). The mean number of infections and of infections requiring antibiotics decreased during IgG replacement significantly. Current health according to EQ-5D-5L improved from 57 (t\n                      <jats:sub>0<\/jats:sub>\n                      ) to 68 (t\n                      <jats:sub>6<\/jats:sub>\n                      ), compared to 73 in the CG.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>During the course of IgG replacement patients reported fewer and less severe infections. Their health assessment improved but still was inferior to the healthy CG.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12865-020-00368-7","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T09:03:52Z","timestamp":1593421432000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Health status and infections in patients with symptomatic primary and secondary immunoglobulin G (IgG) deficiencies receiving intravenous IgG replacement"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7594-9398","authenticated-orcid":false,"given":"Rudolf","family":"Weide","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Schardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Koenigsmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burkhard","family":"Otremba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark-Oliver","family":"Zahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Wierecky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Hensel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Klausmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Fleckenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ehscheidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Feiten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,29]]},"reference":[{"issue":"7","key":"368_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2217\/imt.14.54","volume":"6","author":"JG Peter","year":"2014","unstructured":"Peter JG, Chapel H. Immunoglobulin replacement therapy for primary immunodeficiencies. Immunotherapy. 2014;6(7):853\u201369.","journal-title":"Immunotherapy."},{"key":"368_CR2","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3389\/fimmu.2014.00626","volume":"5","author":"N Compagno","year":"2014","unstructured":"Compagno N, Malipiero G, Cinetto F, Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front Immunol. 2014;5:626.","journal-title":"Front Immunol"},{"issue":"3","key":"368_CR3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/cei.12915","volume":"188","author":"S Jolles","year":"2017","unstructured":"Jolles S, Chapel H, Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. Clin Exp Immunol. 2017;188(3):333\u201341.","journal-title":"Clin Exp Immunol"},{"key":"368_CR4","unstructured":"Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg). https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-core-smpc-human-normal-immunoglobulin-intravenous-administration-ivig-rev-5_en.pdf. Accessed 22 June 2019."},{"issue":"1","key":"368_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1365-2141.1994.tb05002.x","volume":"88","author":"H Chapel","year":"1994","unstructured":"Chapel H, Dicato M, Gamm H, Brennan V, Ries F, Bunch C, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes. Br J Haematol. 1994;88(1):209\u201312.","journal-title":"Br J Haematol"},{"issue":"14","key":"368_CR6","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1056\/NEJM198810063191403","volume":"319","author":"RP Gale","year":"1988","unstructured":"Gale RP, Chapel HM, Bunch C, Rai KR, Foon K, Courter SG, et al. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med. 1988;319(14):902\u20137.","journal-title":"N Engl J Med"},{"issue":"1","key":"368_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/j.1365-2257.1995.tb00322.x","volume":"17","author":"BJ Boughton","year":"1995","unstructured":"Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol. 1995;17(1):75\u201380.","journal-title":"Clin Lab Haematol"},{"issue":"2","key":"368_CR8","first-page":"121","volume":"81","author":"S Molica","year":"1996","unstructured":"Molica S, Musto P, Chiurazzi F, Specchia G, Brugiatelli M, Cicoira L, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica. 1996;81(2):121\u20136.","journal-title":"Haematologica."},{"key":"368_CR9","doi-asserted-by":"publisher","unstructured":"Raanani P, Gafter-Gvili A, Paul M, Ben-Bassat I, Leibovici L, Shpilberg O. Immunoglobulin prophylaxis in hematological malignancies and hematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2008;(4):CD006501. https:\/\/doi.org\/10.1002\/14651858.CD006501.pub2.","DOI":"10.1002\/14651858.CD006501.pub2"},{"issue":"10","key":"368_CR10","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality Life Res. 2011;20(10):1727\u201336.","journal-title":"Quality Life Res"},{"issue":"1","key":"368_CR11","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1186\/s12889-019-7623-2","volume":"19","author":"S Boczor","year":"2019","unstructured":"Boczor S, Daubmann A, Eisele M, Blozik E, Scherer M. Quality of life assessment in patients with heart failure: validity of the German version of the generic EQ-5D-5L. BMC Public Health. 2019;19(1):1464.","journal-title":"BMC Public Health"},{"issue":"4","key":"368_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1469-8986.1987.tb00324.x","volume":"24","author":"MW Vasey","year":"1987","unstructured":"Vasey MW, Thayer JF. The continuing problem of false positives in repeated measures ANOVA in psychophysiology: a multivariate solution. Psychophysiology. 1987;24(4):479\u201386.","journal-title":"Psychophysiology."},{"issue":"7","key":"368_CR13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/1348-0421.12060","volume":"57","author":"G Gunther","year":"2013","unstructured":"Gunther G, Dreger B. Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections. Microbiol Immunol. 2013;57(7):527\u201335.","journal-title":"Microbiol Immunol"},{"issue":"19","key":"368_CR14","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1055\/s-0041-102631","volume":"140","author":"R Weide","year":"2015","unstructured":"Weide R, Feiten S, Friesenhahn V, Heymanns J, Kleboth K, Thomalla J, et al. Immunoglobulin substitution in patients with indolent non-Hodgkin's lymphoma. Deutsche medizinische Wochenschrift (1946). 2015;140(19):e201\u20136.","journal-title":"Deutsche medizinische Wochenschrift (1946)"},{"issue":"7","key":"368_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of Immunoglobulin Levels, infectious risk, and mortality with rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2018;1(7):e184169.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"368_CR16","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/cei.13210","volume":"194","author":"J Hajjar","year":"2018","unstructured":"Hajjar J, Kutac C, Rider NL, Seeborg FO, Scalchunes C, Orange J. Fatigue and the wear-off effect in adult patients with common variable immunodeficiency. Clin Exp Immunol. 2018;194(3):327\u201338.","journal-title":"Clin Exp Immunol"},{"issue":"13","key":"368_CR17","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1002\/cncr.32040","volume":"125","author":"N Mounier","year":"2019","unstructured":"Mounier N, Anthony S, Busson R, Thieblemont C, Ribrag V, Tilly H, et al. Long-term fatigue in survivors of non-Hodgkin lymphoma: the lymphoma study association SIMONAL cross-sectional study. Cancer. 2019;125(13):2291\u20139.","journal-title":"Cancer."}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-020-00368-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-020-00368-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-020-00368-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T14:20:13Z","timestamp":1723126813000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-020-00368-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,29]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["368"],"URL":"https:\/\/doi.org\/10.1186\/s12865-020-00368-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-17742\/v1","asserted-by":"object"}]},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,29]]},"assertion":[{"value":"17 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the ethics committee of Rhineland-Palatinate, Germany.Written informed consent was obtained from all participants. All procedures performed in this study were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}